William F. Pierce

2.5k total citations · 1 hit paper
26 papers, 1.1k citations indexed

About

William F. Pierce is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, William F. Pierce has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in William F. Pierce's work include HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). William F. Pierce is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). William F. Pierce collaborates with scholars based in United States and Japan. William F. Pierce's co-authors include Richard Pazdur, Shenghui Tang, Paul G. Kluetz, Kirsten B. Goldberg, Laleh Amiri‐Kordestani, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Rajeshwari Sridhara and Todd R. Palmby and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Neuroscience.

In The Last Decade

William F. Pierce

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by William F. Pierce

Since Specialization

Citations

This map shows the geographic impact of William F. Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William F. Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William F. Pierce more than expected).

Fields of papers citing papers by William F. Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William F. Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William F. Pierce. The network helps show where William F. Pierce may publish in the future.

Co-authorship network of co-authors of William F. Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of William F. Pierce. A scholar is included among the top collaborators of William F. Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William F. Pierce. William F. Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer 2025 ·Journal of Clinical Oncology ·Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H. Fiero, Hui Zhang, Xin Gao, Matthew Neilson, Kirsten B. Goldberg, Abhilasha Nair, Tiffany K. Ricks, William F. Pierce, Nicole Gormley, Marc R. Theoret, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	1
2	FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ 2025 ·Clinical Cancer Research ·Brian L. Heiss, Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, (unknown), Salaheldin S. Hamed, Haw-Jyh Chiu, Tiffany K. Ricks, (unknown), (unknown), (unknown), (unknown), William F. Pierce, John K. Leighton, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Paul G. Kluetz, Daniel L. Suzman	2
3	US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer 2025 ·Journal of Clinical Oncology ·Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, (unknown), (unknown), Lauren Price, Nam Atiqur Rahman, Haw-Jyh Chiu, (unknown), Tiffany K. Ricks, Mallorie H. Fiero, Shenghui Tang, Christy Osgood, William F. Pierce, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	1
4	US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer 2025 ·Journal of Clinical Oncology ·Asma Dilawari, Hui Zhang, Mirat Shah, Xin Gao, Mallorie H. Fiero, (unknown), William F. Pierce, Bronwyn D. Mixter, Richard Pazdur, Laleh Amiri‐Kordestani	2
5	FDA Approval Summary: Capecitabine Labeling Update under Project Renewal 2024 ·Clinical Cancer Research ·Sundeep Agrawal, (unknown), William F. Pierce, (unknown), (unknown), Melanie Royce, Christy Osgood, Laleh Amiri‐Kordestani, Haw-Jyh Chiu, Tiffany K. Ricks, (unknown), Jeanne Fourie Zirkelbach, Rosane Charlab, Michael Pacanowski, Tamy Kim, Richard Pazdur, Paul G. Kluetz, Jennifer Gao	0
6	FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma 2024 ·Clinical Cancer Research ·Michael H. Brave, William F. Maguire, Chana Weinstock, (unknown), Xin Gao, (unknown), Jingyu Yu, Wentao Fu, (unknown), William F. Pierce, Elaine Chang, Jeannette Dinin, Mallorie H. Fiero, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani, Daniel L. Suzman	14
7	FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma 2024 ·Clinical Cancer Research ·Jaleh Fallah, Brian L. Heiss, Hee‐Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce, (unknown), (unknown), Mallorie H. Fiero, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, Daniel L. Suzman	9
8	FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2023 ·Clinical Cancer Research ·Jennifer Gao, Christy Osgood, (unknown), Erik Bloomquist, Shenghui Tang, (unknown), Tiffany K. Ricks, (unknown), William F. Pierce, Donna R. Rivera, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	3
9	US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer 2023 ·Journal of Clinical Oncology ·Preeti Narayan, Asma Dilawari, Christy Osgood, (unknown), Erik Bloomquist, William F. Pierce, (unknown), Shyam Kalavar, Marina Kondratovich, (unknown), Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	34
10	FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer breakdown → 2022 ·Clinical Cancer Research ·Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, (unknown), Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, (unknown), Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz	127
11	FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer 2022 ·Clinical Cancer Research ·Mirat Shah, Christy Osgood, Anup Amatya, Mallorie H. Fiero, William F. Pierce, Abhilasha Nair, (unknown), (unknown), Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	56
12	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer 2021 ·Clinical Cancer Research ·Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, (unknown), (unknown), (unknown), William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver	118
13	Progressive long‐term spatial memory loss following repeat concussive and subconcussive brain injury in mice, associated with dorsal hippocampal neuron loss, microglial phenotype shift, and vascular abnormalities 2020 ·European Journal of Neuroscience ·Marcia G. Honig, (unknown), (unknown), (unknown), (unknown), (unknown), William F. Pierce, (unknown), Anton Reiner	16
14	FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs 2020 ·Clinical Cancer Research ·Paul G. Kluetz, Patricia Keegan, George D. Demetri, Katherine A. Thornton, Joohee Sul, (unknown), (unknown), Laurie B. Burke, R. Donald Harvey, (unknown), Sundeep Agrawal, Abhilasha Nair, Martha Donoghue, William F. Pierce, Stacy S. Shord, Jennifer Gao, Richard Pazdur	8
15	FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer 2018 ·Clinical Cancer Research ·Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R. Palmby, Kirsten B. Goldberg, (unknown), Paresma Patel, (unknown), Amy Tilley, William F. Pierce, Amna Ibrahim, Gideon M. Blumenthal, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur	88
16	U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer 2018 ·Clinical Cancer Research ·Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani, Joyce Cheng, Shenghui Tang, (unknown), (unknown), Todd R. Palmby, Xianhua Cao, (unknown), Qi Liu, Jingyu Yu, William F. Pierce, Selena Daniels, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Gideon M. Blumenthal, Julia A. Beaver, Richard Pazdur	75
17	Essential Medications for Patients With Suspected or Confirmed Ebola Virus Disease in Resource-Limited Environments 2017 ·Military Medicine ·William F. Pierce, (unknown), (unknown), (unknown), (unknown), (unknown), Kimberly Andrews, Richard Childs, (unknown), (unknown), (unknown)	1
18	The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making 2012 ·The Journal of Clinical Pharmacology ·Jun Yang, Hong Zhao, Christine Garnett, Atiqur Rahman, Jogarao Gobburu, William F. Pierce, (unknown), Jeffery J. Summers, Patricia Keegan, Brian Booth, Yaning Wang	77
19	Pharmacist readiness roles for emergency preparedness 2011 ·American Journal of Health-System Pharmacy ·(unknown), Michael Montello, (unknown), William F. Pierce, (unknown)	34
20	The Career Education Concept. 1973 ·American education ·William F. Pierce	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact